Emerging studies further support the study of the prototypic Th2 isotype, IgE as a means to combat tumours when directed against cancer antigens through promoting the interaction between effector and cancer cells, and stimulating CTLs via antigen cross‐presentation. The gene discussed is IGHE; the disease is neoplasm.